surpass 2 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Patient-Reported Outcomes in People with
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 13 - Nov 18
























